Bioaffinity Technologies Inc   (BIAF)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $2.3500 $0.25 11.905%
Day's High: $2.37 Week Perf: 14.08 %
Day's Low: $ 1.94 30 Day Perf: 52.6 %
Volume (M): 93 52 Wk High: $ 2.49
Volume (M$): $ 218 52 Wk Avg: $1.66
Open: $2.23 52 Wk Low: $0.95

 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Bioaffinity Technologies Inc
Bioaffinity Technologies Inc. is a biotechnology company that focuses on the development and commercialization of innovative diagnostic tests. The company specializes in creating highly sensitive and specific tests for the early detection of various diseases, including cancer. Bioaffinity Technologies utilizes a proprietary technology called the Affinity Matrix, which allows for the detection of disease-specific biomarkers. This technology offers significant advantages over traditional diagnostic methods, such as improved accuracy and faster results. The company's goal is to improve patient outcomes by providing healthcare professionals with reliable and timely diagnostic tools.

   Company Address: 22211 W Interstate 10 San Antonio 78257 TX
   Company Phone Number: 698-5334   Stock Exchange / Ticker: NASDAQ BIAF
   BIAF is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Butterfly Network Inc

Butterfly Network Inc Surprises with Decreased Loss Per Share, Revenue Decline in Q4 2023

Butterfly Network Inc Reports Decreased Loss Per Share, Declining Revenue for Q4 2023
BURLINGTON, Mass. and NEW YORK - Butterfly Network, Inc. (NYSE: BFLY), a digital health company focused on portable, semiconductor-based ultrasound technology, announced its financial results for the quarter and year ended December 31, 2023. The company also provided an update on its business activities. Butterfly Network aims to make medical imaging more accessible through its innovative product offerings, software solutions, and educational programs.
For the financial period closing December 31, 2023, Butterfly Network reported a loss of $-0.21 per share, showing an improvement from the loss of $-0.31 per share in the previous year. However, there was an increased loss compared to the previous reporting period, from $-0.13 per share. The company's revenue declined by 14.346% to $17.08 million from $19.94 million, in the comparable reporting period a year prior. Nevertheless, sequentially, the revenue advanced by 11.013%, from $15.38 million.

Veracyte Inc

Veracyte Inc Shatters Expectations with Remarkable Revenue Growth in Q4 2023

Veracyte Inc (VCYT) is a company that has recently experienced significant growth in its revenue. In the Dec 31, 2023 report, the company announced a surge in revenue by 22.295% to $98.20 million compared to the similar quarter a year ago. This highlights the company's ability to generate more sales and increase its market share.
However, it is important to note that Veracyte Inc has also seen its deficit expand at $-0.38 per share. It is crucial to analyze the reasons behind this deficit and whether it is a temporary setback or a long-term concern. Sequentially, the company seems to be improving, as its EPS has improved from $-0.41 per share and revenue has advanced by 8.979% from $90.11 million.
During the October to December 31, 2023 financial period, Veracyte Inc realized a net deficit of $-28.293 million, which is larger than the deficit of $-3.844 million a year ago. It is important to dig deeper into the reasons behind this increased deficit and assess whether it is a result of strategic investments or operational inefficiencies.

Caredx Inc

Caredx Inc. Sees Double-Digit Revenue Decline Through Fiscal Year Ending December 31, 2023

The stock market can be a rollercoaster ride for investors, with its ups and downs and constant changes. However, it is important to remember that even in challenging times, there are always opportunities to be found. One company that has recently faced some setbacks is Caredx Inc. Despite reporting a rise in losses for the fourth quarter of 2023, there are several positive factors investors should consider.
In the financial report, Caredx Inc. disclosed a shortfall per share that inched up to $-2.18 from $-0.34. While this may seem concerning at first, it is important to note that this increase is primarily due to weak demand, rather than any fundamental issues with the company itself. It is crucial to analyze the root causes behind such setbacks in order to make informed investment decisions.

Castle Biosciences Inc

Castle Biosciences Inc reports $0.04 million tax charge in Q4 financial results

Castle Biosciences Inc is a medical laboratory company that specializes in providing diagnostic tests and services for the detection and monitoring of various diseases. The company recently reported its financial performance for the October to December 2023 period, revealing positive results and strong growth.
During this period, Castle Biosciences Inc saw a significant improvement in its earnings per share (EPS), with a decrease in loss per share from $-0.76 to $-0.09 compared to the same period the previous year. This improvement in EPS was also evident when comparing to the previous quarter's loss per share of $-0.26. These positive results indicate that the company has been able to reduce its losses and move closer to profitability.

Natera Inc

Natera Inc Sees Strong Growth in Shares and Financial Performance in Recent Fiscal Period

Natera Inc, a global leader in cell-free DNA testing, has recently recorded a solid gain of 5.37% in its shares during the past five trading days. This increase brings the share price to a high of 19.82% during the first quarter of 2024. Additionally, Natera Inc shares have reached their 52-week high.
In terms of financial performance, Natera Inc has shown significant improvement. In the most recent fiscal period, the company reported a decrease in loss per share to $-0.57, compared to $-1.31 a year prior. The earnings per share (EPS) also improved from $-0.95 in the previous reporting season. Furthermore, the revenue jumped by 43.2% to $311.11 million from $217.25 million in the same reporting season a year ago. Sequentially, the revenue improved by 15.952% from $268.31 million.


Bioaffinity Technologies Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com